Stocktoria
Lexeo Therapeutics, Inc. LXEO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-11-03
Lexeo Therapeutics, Inc. statistics & valuation
Market cap$373.0M
P / B1.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating margin | — | — | — | -9252.1% |
| Net margin | — | — | — | -9063.8% |
| FCF margin | — | — | — | -8445.3% |
| Return on assets | -37.2% | -66.9% | -47.5% | -61.1% |
| Return on equity | -40.5% | -84.2% | -58.5% | 52.5% |
| Current ratio | 11.21 | 5.52 | 7.21 | 5.58 |
Source: SEC EDGAR filings · CIK 0001907108 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.